What is Zacks Small Cap’s Forecast for RVPH FY2024 Earnings?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Stock analysts at Zacks Small Cap lifted their FY2024 earnings estimates for shares of Reviva Pharmaceuticals in a research note issued to investors on Monday, December 23rd. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings of ($0.97) per share for the year, up from their previous estimate of ($0.98). The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($1.01) per share. Zacks Small Cap also issued estimates for Reviva Pharmaceuticals’ Q4 2024 earnings at ($0.22) EPS.

Separately, EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd.

Reviva Pharmaceuticals Stock Performance

RVPH stock opened at $1.86 on Wednesday. The stock has a market capitalization of $62.20 million, a PE ratio of -1.68 and a beta of -0.02. The company has a fifty day moving average of $1.41 and a 200-day moving average of $1.25. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $5.67.

Institutional Trading of Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC grew its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 278,496 shares of the company’s stock after buying an additional 42,376 shares during the quarter. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 at the end of the most recent quarter. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.